Patents Assigned to Genentech
  • Methods of treating hedgehog-related diseases with an anti-LGR5 antibody
    Patent number: 10246515
    Abstract: Provided herein are methods of using anti-LGR5 antibodies, for example, for treating a hedgehog-related disease including basal cell carcinoma.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: April 2, 2019
    Assignee: Genentech, Inc.
    Inventors: Frederic J. De Sauvage, Brian Biehs
  • Nucleic acids encoding bispecific antibodies binding to beta-Klotho and fibroblast growth factor receptor 1
    Patent number: 10246518
    Abstract: The presently disclosed subject matter provides antibodies that bind KLB and FGFR1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on FGFR1 and binds to an epitope present on KLB.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: April 2, 2019
    Assignee: Genentech, Inc.
    Inventors: Yongmei Chen, James Ernst, Hok Seon Kim, Junichiro Sonoda, Christoph Spiess, Scott Stawicki, Yan Wu
  • NSP4 inhibitors and methods of use
    Patent number: 10246519
    Abstract: The invention provides NSP4 inhibitors (such as anti-NSP4 antibodies) and methods of using the same.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: April 2, 2019
    Assignee: Genentech, Inc.
    Inventors: Shuo-Yen Jack Lin, Daniel K. Kirchhofer, Menno Van Lookeren Campagne
  • Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
    Patent number: 10246461
    Abstract: The invention relates generally to pharmaceutical tablet compositions comprising fumaric acid and the compound (S)-2-(3?-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4?-bipyridin]-2?-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one free base that is an inhibitor of Bruton's tyrosine kinase. The invention further relates to amorphous solid dispersions comprising at least one polymer and the Bruton's kinase inhibitor free base compound. The invention further relates to crystalline mesylate salts, crystalline chloride salts and crystalline sulfate salts of the Bruton's kinase inhibitor free base compound. In some aspects, the crystalline salts are single polymorphs.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: April 2, 2019
    Assignee: Genentech, Inc.
    Inventors: Chen Mao, Dawen Kou, Po-Chang Chiang
  • INHIBITION OF IL-17 PRODUCTION
    Publication number: 20190092829
    Abstract: The invention concerns inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23). The invention further concerns the use of IL-23 antagonists in the treatment of inflammatory diseases characterized by the presence of elevated levels of IL-17. IL-23 antagonists include, without limitation, antibodies specifically binding to a subunit or IL-17 or an IL-17 receptor. The invention additionally concerns induction of IL-7 production by using an IL-23 agonist.
    Type: Application
    Filed: April 19, 2018
    Publication date: March 28, 2019
    Applicant: Genentech, Inc.
    Inventor: Austin L. GURNEY
  • Anti-CLL-1 antibodies and immunoconjugates
    Patent number: 10239947
    Abstract: The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: March 26, 2019
    Assignee: Genentech, Inc.
    Inventors: Bing Zheng, Andrew Polson, Cecilia Chiu, Wei-Ching Liang, Yan Wu
  • Cancer treatment with c-met antagonists and correlation of the latter with HGF expression
    Patent number: 10240207
    Abstract: The present invention concerns cancer biomarkers. In particular, the invention concerns HGF as a biomarker for patient selection and patient prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: March 26, 2019
    Assignee: Genentech, Inc.
    Inventors: Wei Yu, David Shames, Hartmut Koeppen, See Phan, Sandra Rost
  • Process for making compounds for use in the treatment of cancer
    Patent number: 10239858
    Abstract: Disclosed herein is a process of making a compound of formula I The compound of formula I is an inhibitor of MEK and thus can be used to treat cancer.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: March 26, 2019
    Assignees: EXELIXIS, INC., GENENTECH, INC.
    Inventors: Sriram Naganathan, Nathan Guz, Matthew Pfeiffer, C. Gregory Sowell, Tracy Bostick, Jason Yang, Amit Srivastava, Neel Kumar Anand
  • METHODS OF PRODUCING TWO CHAIN PROTEINS IN BACTERIA
    Publication number: 20190085045
    Abstract: Provided herein are methods of producing a recombinant polypeptide containing two chains, such as an immune mobilizing monoclonal T-cell receptor against cancer (ImmTAC) protein including an alpha chain and a beta chain. In particular, methods are provided for producing heterologous secretory proteins in bacteria through utilization of optimized expression vectors and culture processes.
    Type: Application
    Filed: July 25, 2018
    Publication date: March 21, 2019
    Applicant: Genentech, Inc.
    Inventors: James GIULIANOTTI, Dorothea E. REILLY, Kieran AURORI, Laura C. SIMMONS
  • IMMUNOGLOBULIN VARIANTS WITH ALTERED BINDING TO PROTEIN A
    Publication number: 20190085094
    Abstract: Variant immunoglobulins with one or more amino acid modifications in the VH region that have altered binding to Staphylococcus aureus protein A, and methods of using the same are provided.
    Type: Application
    Filed: November 16, 2018
    Publication date: March 21, 2019
    Applicant: Genentech, Inc.
    Inventors: Yik Andy Yeung, Henry B. Lowman
  • PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF
    Publication number: 20190083643
    Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.
    Type: Application
    Filed: October 3, 2018
    Publication date: March 21, 2019
    Applicant: Genentech, Inc.
    Inventors: Ho Huat Lee, Moana Tercel, John A. Flygare, Janet Gunzner-Toste, Thomas H. Pillow, Brian Safina, Leanna Staben, Vishal Verma, BinQing Wei, Guiling Zhao
  • ANTI-Ly6E ANTIBODIES AND METHODS OF USE
    Publication number: 20190085089
    Abstract: The invention provides anti-Ly6E antibodies, immunoconjugates and methods of using the same.
    Type: Application
    Filed: July 31, 2018
    Publication date: March 21, 2019
    Applicant: Genentech, Inc.
    Inventors: Jyoti Asundi, Ron Firestein, Paul Polakis, Chie Sakanaka, Peter Chang, Rayna Takaki Venook
  • MUTANT SMOOTHENED AND METHODS OF USING THE SAME
    Publication number: 20190083646
    Abstract: The emergence of mutations in tyrosine kinases following treatment of cancer patients with molecular-targeted therapy represents a major mechanism of acquired drug resistance. Here, mutations in the serpentine receptor, Smoothened (SMO) are described, which result in resistance to a Hedgehog (Hh) pathway inhibitor, such as in medulloblastoma. Amino acid substitutions in conserved residues of SMO maintain Hh signaling, but result in the inability of the Hh pathway inhibitor, GDC-0449, to suppress the pathway. In some embodiments, the disclosure provides for novel mutant SMO proteins and nucleic acids and for screening methods to detect SMO mutations and methods to screen for drugs that specifically modulate mutant SMO exhibiting drug resistance.
    Type: Application
    Filed: August 3, 2018
    Publication date: March 21, 2019
    Applicants: CURIS, INC., GENENTECH, INC.
    Inventors: Hayley SHARPE, Steven GENDREAU
  • SYSTEMS AND METHODS FOR TWO-DIMENSIONAL CHROMATOGRAPHY
    Publication number: 20190079062
    Abstract: Provided are two-dimensional chromatography systems and methods for separating and/or analyzing complex mixtures of organic compounds. In particularly, a two-dimensional reversed-phase liquid chromatography (RPLC)—supercritical fluid chromatography (SFC) system is described including a trapping column at the interface which collects the analytes eluted from the first dimension chromatography while letting the RPLC mobile phase pass through. The peaks of interest from the RPLC dimension column are effectively focused as sharp concentration pulses on the trapping column, which is subsequently injected onto the second dimension SFC column. The system can be used for simultaneous achiral and chiral analysis of pharmaceutical compounds. The first dimension RPLC separation provides the achiral purity result, and the second dimension SFC separation provides the chiral purity result (enantiomeric excess).
    Type: Application
    Filed: September 7, 2018
    Publication date: March 14, 2019
    Applicant: Genentech, Inc.
    Inventors: Cadapakam VENKATRAMANI, Mohammad AL-SAYAH
  • USE OF KLK5 ANTAGONISTS FOR TREATMENT OF A DISEASE
    Publication number: 20190078160
    Abstract: Provided herein are methods of treating a subject, methods of predicting the response of a subject and selecting a subject suffering from a disease associated with KLK5, such as asthma or Netherton Syndrome. In particular, provided herein are uses of KLK5 antagonists for the treatment or diagnosis of asthma or Netherton Syndrome, such as an antibody or an Fc fusion polypeptide as well as pharmaceutical formulations comprising the same.
    Type: Application
    Filed: April 20, 2018
    Publication date: March 14, 2019
    Applicant: Genentech, Inc.
    Inventors: Amy Dressen, David B. Iaea, Moulay Hicham Alaoui Ismaili, Janet K. Jackman, Robert A. Lazarus, Kelly Loyet, Henry R. Maun, Brian L. Yaspan, Tangsheng Yi, Joseph R. Arron, Hilda Y. Hernandez-Barry
  • Estrogen receptor modulators and uses thereof
    Patent number: 10227334
    Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: March 12, 2019
    Assignee: Genentech, Inc.
    Inventors: Mehmet Kahraman, Steven P. Govek, Nicholas D. Smith, Jeffrey H. Hager, Edna Chow Maneval
  • Anti-CLL-1 antibodies and immunoconjugates
    Patent number: 10227412
    Abstract: The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: March 12, 2019
    Assignee: Genentech, Inc.
    Inventors: Bing Zheng, Andrew Polson, Cecilia Chiu, Wei-Ching Liang, Yan Wu
  • Methods and composition for secretion of heterologous polypeptides
    Patent number: 10227416
    Abstract: The present invention relates generally to the fields of molecular biology and protein technology. More specifically, the invention concerns signal sequences for the secretion of heterologous polypeptide from bacteria. The invention also concerns recombinant polypeptides and uses thereof.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: March 12, 2019
    Assignee: GENENTECH, INC.
    Inventors: Matthew Marrichi, Dorothea E. Reilly
  • GENE DETECTION ASSAY FOR IMPROVING THE LIKELIHOOD OF AN EFFECTIVE RESPONSE TO AN ErbB ANTAGONIST CANCER THERAPY
    Publication number: 20190070291
    Abstract: The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing EGFR, as determined by a gene amplification assay, with an EGFR antagonist. Such method comprises administering a cancer-treating dose of the EGFR antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells erbB1 gene has been found to be amplified e.g., by fluorescent in situ hybridization. EGFR antagonists described include an anti-EGFR antibody.
    Type: Application
    Filed: November 7, 2018
    Publication date: March 7, 2019
    Applicant: Genentech, Inc.
    Inventor: Robert D. Mass
  • THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20190071404
    Abstract: Compounds of Formula (I): and salts thereof, and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: November 5, 2018
    Publication date: March 7, 2019
    Applicant: Genentech, Inc.
    Inventors: James John Crawford, Mark Zak, Terry Kellar, Yun-Xing Cheng, Wei Li, F. Anthony Romero, Paul Gibbons, Guiling Zhao, Gregory Hamilton, Simon Charles Goodacre